FDA Panel Votes 11-2 In Favor of Usage for GlaxoSmithKline's (GSK) Votrient

GlaxoSmithKline (NYSE: GSK) announced today that the Oncologic Drugs Advisory Committee to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma who have received prior chemotherapy, noting that those with gastrointestinal stromal tumours (GIST) and adipocytic sarcomas were not included in the Phase III trial. The ODAC reviewed findings from one Phase III clinical study and one Phase II study.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Aligos Therapeutics Inc. (ALGS) Presents Positive Data from the ALG-097558 Phase 1 Study
• Western Digital (WDC) posts FQ3 earnings, revenue beat; shares down
• Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble